Archives
Repurposing FDA-Approved Drugs to Modulate DNA Repair in CRI
Repurposing FDA-Approved Drugs to Modulate DNA Repair in CRISPR Editing
Study Background and Research Question
DNA double-strand breaks (DSBs) are critical lesions that threaten genome integrity and are repaired by multiple cellular pathways. In the context of genome editing, especially CRISPR-Cas9 systems, controlled induction of DSBs at specific loci underpins targeted gene disruption, correction, and insertion. However, the intrinsic repair mechanisms—primarily non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR)—introduce variability in editing outcomes, ranging from small indels to precise sequence changes. The ability to modulate these pathways pharmacologically is of high interest for improving editing precision, minimizing off-target effects, and enabling synthetic lethality approaches in cancer therapy (reference paper).
Key Innovation from the Reference Study
The referenced study represents the first large-scale, systematic screen of >7,000 FDA-approved drugs for their effects on DSB repair pathway choice in human induced pluripotent stem cells (hiPSCs). By quantifying how these compounds modulate NHEJ, MMEJ, and HDR outcomes during CRISPR-mediated genome editing, the authors identify candidate molecules that enhance or inhibit specific repair routes. This resource enables rational selection of drugs to steer genome editing outcomes, enhance template-directed repair, or induce synthetic lethality in cancer models (reference paper).
Methods and Experimental Design Insights
The study leveraged a high-throughput screening approach using 409B2 hiPSCs engineered to express doxycycline-inducible Cas9 (iCRISPR). Cells were edited at the FRMD7 locus during drug treatment, and after recovery, survival was assessed via resazurin fluorescence. DNA was extracted, and editing outcomes were quantified by Illumina sequencing, allowing pathway-specific assignment of indels (NHEJ: <2 bp microhomology, MMEJ: ≥2 bp microhomology, HDR: precise edits) (reference paper).
Each drug was tested in a single replicate due to scale, but the large number of conditions and robust sequencing quantification enabled statistical identification of significant modulators. The analysis also incorporated functional studies on key regulatory proteins, such as ESR2 and AOX1, using gene silencing to evaluate combinatorial effects on pathway choice.
Protocol Parameters
- assay | hiPSC genome editing | 409B2 line, doxycycline-inducible Cas9 | enables inducible, controlled DSB formation in human pluripotent cells | reference_paper
- drug screen | >7,000 conditions | FDA-approved drugs, single replicate each | maximizes translational relevance and identifies clinically actionable modulators | reference_paper
- readout | resazurin fluorescence | post-editing cell viability | screens for survival impacts and synthetic lethality | reference_paper
- sequencing | Illumina short-read | quantifies precise vs. indel outcomes | supports high-throughput, pathway-specific outcome assessment | reference_paper
- workflow suggestion | Dantrolene sodium salt at 5–10 μM (DMSO stock) | calcium signaling modulation in gene-editing or cytotoxicity assays | recommended for optimizing calcium-dependent pathways in similar hiPSC models | workflow_recommendation
Core Findings and Why They Matter
Several major advances emerge from this comprehensive drug repurposing screen:
- Identification of pathway modulators: The screen uncovered drugs that selectively inhibit or enhance NHEJ, MMEJ, or HDR repair, providing new tools to shift editing outcomes. For example, NHEJ inhibitors can increase HDR-mediated precise edits by limiting error-prone repair (reference paper).
- Role of regulatory proteins: Silencing ESR2 or AOX1 impacts several DNA repair proteins, including ATM and 53BP1. Notably, ESR2 knockdown combined with NHEJ inhibition yielded a 4.6-fold increase in HDR, suggesting synergistic strategies for precise editing (reference paper).
- Synthetic lethality potential: The study identified drugs that are selectively toxic when NHEJ or HDR pathways are blocked, providing a framework for cancer therapy targeting repair-deficient tumors (reference paper).
Collectively, these findings enable researchers to fine-tune gene-editing outcomes, improve disease modeling fidelity, and explore novel treatment paradigms in oncology.
Comparison with Existing Internal Articles
Several internal resources expand on the practical aspects of modulating calcium signaling and DNA repair in gene-editing workflows. For instance, "Dantrolene Sodium Salt: Precision Ryanodine Receptor Antagonist Use" highlights the role of dantrolene sodium salt as a nanomolar-range ryanodine receptor antagonist for precise intracellular calcium modulation, which can impact DNA repair outcomes in translational research. Similarly, "Dantrolene Sodium Salt: Unveiling New Frontiers in RyR Signaling and DNA Repair" discusses the calmodulin-dependent mechanism of dantrolene, illustrating its potential for research in both calcium signaling and genome editing contexts. These articles complement the reference study by providing workflow-centric insights and troubleshooting strategies for integrating ryanodine receptor antagonists such as dantrolene sodium salt into advanced research protocols.
Limitations and Transferability
While the study's large-scale screen offers a valuable compendium of DNA repair modulators, several limitations must be acknowledged. Single-replicate testing per drug may overlook subtle effects or outliers, and results may be specific to the hiPSC line and target locus used. Moreover, while many drugs are FDA-approved, their safety and efficacy in the context of genome editing or synthetic lethality require further validation in additional cell types and in vivo models. The transferability of findings to non-pluripotent cells or primary tissues remains an important area for follow-up (reference paper).
Why this cross-domain matters, maturity, and limitations
The intersection of DNA repair modulation and pharmacological intervention has implications for multiple research domains—ranging from precise gene editing in disease models to combinatorial cancer therapies exploiting synthetic lethality. However, while mechanistic links between calcium signaling and DNA repair (e.g., via ryanodine receptor antagonists) are supported in preclinical models (internal article), their translation to clinical workflows is still emerging. Further studies are needed to establish robust, context-specific protocols and to define the limits of pathway modulation in differentiated or pathological cell types.
Research Support Resources
Researchers aiming to apply these findings can leverage validated calcium signaling modulators such as Dantrolene, sodium salt (SKU B6329), a potent ryanodine receptor antagonist with nanomolar activity and high purity, to support genome editing, cell viability, and calcium signaling assays (workflow recommendation). APExBIO provides detailed quality control data for this compound, facilitating reliable experimental design in studies where modulation of intracellular calcium and DNA repair pathways is central.